Descriptiopn
Name:Vivian
Whatsapp:+86 19831933967
Email:caoquan3@xtkstech.com
PNC-27 is an innovative therapeutic agent with the following details:
English name: PNC-27
CAS number: 1159861-00-3
PNC-27 is a synthetic anti-cancer peptide derived from the tumor suppressor protein p53. With its unique molecular design and mechanism of action, it has shown great potential in targeted therapy research for various cancers while minimizing damage to normal cells.
Developed by Dr. Joseph M. Dahabieh and his team at the State University of New York Downstate Medical Center in the early 21st century, the peptide was initially designed to mimic the MDM-2 binding domain in p53, achieving targeted anticancer effects.
Precise Targeting of Cancer Cells:
HDM-2 protein is a key regulatory factor that inhibits p53 function. It is highly overexpressed on the cell membranes of various cancer cells, while its expression level is extremely low or absent in normal cells. PNC-27 can bind to HDM-2 on cancer cell membranes with high affinity. This targeting ability is the core reason for its distinction between cancer cells and normal cells, as well as an important factor contributing to its low toxicity.
Inducing Cancer Cell Necrosis:
After binding to HDM-2 on cancer cell membranes, PNC-27 first forms a 1:1 complex, which then dimerizes to form transmembrane pores on the cancer cell membrane. This leads to the rapid leakage of intracellular contents, ultimately causing cancer cell lysis and necrosis. The formation of these pores can be directly observed using high-resolution scanning immunoelectron microscopy. Moreover, this process is independent of the status of the intracellular p53 gene—even if the p53 pathway is impaired in cancer cells, PNC-27 can still exert its anticancer effects.
Activating Apoptosis-Related Pathways to Assist Anticancer Effects
In addition to directly lysing cancer cells, it can also induce mitochondrial membrane depolarization and caspase activation in cancer cells, further activating the cell's intrinsic apoptotic pathway and enhancing the killing effect on cancer cells.
Research Application Scenarios and Potential
Adapting to Various Cancer Types:
In preclinical studies, PNC-27 has demonstrated cytotoxic activity against a variety of cancer cell lines, including solid tumors such as lung cancer, colorectal cancer, breast cancer, and pancreatic cancer, as well as hematological malignancies such as leukemia and lymphoma. It has also successfully treated highly metastatic pancreatic tumors and stem cell-rich human acute myeloid leukemia in nude mice without significant off-target effects.
Assisting in the Treatment of Drug-Resistant Cancers
PNC-27 also exhibits cytotoxicity against chemotherapy-resistant cancer strains. This provides a new research direction for addressing the common problem of drug resistance in cancer treatment and is expected to bring new therapeutic ideas to patients who are ineffective against traditional chemotherapy.
Synergistically Enhancing the Efficacy of Other Drugs:
Studies have found that PNC-27 can synergize with various anticancer drugs such as rapamycin, methotrexate, and paclitaxel. It can significantly reduce the half-maximal inhibitory concentration required for these drugs to kill cancer cells and enhance their anticancer effects. Therefore, it is expected to be used as an adjuvant therapeutic drug in combined anticancer regimens.
Significant Advantages:
Compared with traditional chemotherapeutic drugs, the greatest advantages of PNC-27 are its strong selectivity and low toxicity. Traditional chemotherapeutic drugs often cause severe damage to normal cells while killing cancer cells, leading to a series of side effects such as hair loss, nausea, and decreased immunity. In contrast, PNC-27 only targets cancer cells with high HDM-2 expression and causes almost no harm to normal cells, which can greatly reduce treatment-related side effects and improve the quality of life of patients after treatment.
United States
